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dents in the treatment of dementia-related psychosis particularly in two forms: i) 
off-label prescribing-i.e., prescribing AAPs for an unapproved indication against 
FDA-issued warnings on the product label and, ii) polytherapy-i.e., concurrent use 
of two or more AAPs contrary to evidence-based treatment guidelines. Methods: 
The study utilized a sample of nursing home residents, obtained from 2004 National 
Nursing Home Survey database (NNHS). The study sample included residents aged 
65 and over, with at least one prescription for a currently marketed AAP and having 
a primary diagnosis of dementia in accordance with ICD-9 codes. Off-label prescrib-
ing and polytherapy with AAPs served as the study dependent variables, along with 
a systematic analysis of demographic, clinical, social and other factors. Results: 
Out of 13507 nursing home residents in the database, 4955 individuals (36.6%) had 
a primary diagnosis of dementia. About 32% of these were prescribed at least one 
AAPs and less than 1% also used an additional AAPs. Elderly who were aged 80 years 
and over was the group with most prescriptions for AAPs (49%). In a specific popula-
tion affected by schizophrenia and bipolar disorder, where AAP polytherapy may 
be clinically justified (58%) had a prescription for at least one AAP, with olanzapine 
(28%) being the most prescribed. About 7% of this population was also concurrently 
taking at least two AAPs. ConClusions: Overall, the use of polytherapy appears to 
be negligible in the sample diagnosed with dementia. However, in nursing home res-
idents with co-morbidities, polytherapy with AAPs appears to be more pronounced 
compared to the larger dementia population. In addition, off-label prescribing seems 
widespread particularly in older population diagnosed with dementia.
SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
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ASSESSMENT Of STRuCTuRED EMR DATA’S AbIlITY TO PREDICT OR IDENTIfY 
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objeCtives: Assess ability of structured electronic medical record (EMR) data to 
predict or identify a measure of Clinician Labeled Opioid Abuse (CLOA) derived 
from clinicians’ unstructured EMR notes for patients on Chronic Opioid Therapy 
(COT). Methods: Study subjects included 2,752 chronic non-cancer pain patients 
initiating COT during 2008-10 at Group Health Cooperative (Seattle, WA) who 
received at least 2 quarters of COT (≥ 70 days’ supply of an opioid in a quarter) 
within a one-year period. CLOA was derived using Natural Language Processing 
(NLP) techniques based on a custom dictionary of 792 terms to identify mentions 
of opioid addiction, abuse, and overuse written in the clinician’s free text clinical 
notes in the patient’s EMR. CLOA was validated by computer-assisted manual 
review of NLP positive clinical EMR notes. We developed an opioid abuse risk score 
from structured EMR data for the two year period prior to COT Initiation (“prior” 
model), and an opioid abuse risk score from structured EMR data from the quar-
ter of COT initiation through December 2012 (“concurrent” model). Using logistic 
regression, we predicted CLOA status from the prior and concurrent opioid abuse 
risk scores in both learning and validation samples. Results: In the sample, 
100 (3.6%) patients had CLOA, but only 51% of these patients had an ICD-9 diag-
nosis of opioid abuse in concurrent EMR data. The “prior” risk score from struc-
tured data predicted CLOA with an area under the curve of 0.75 in the learning 
sample and 0.74 in the validation sample, while the “concurrent” risk score 
developed from structured data identified CLOA with an area under the curve of 
0.84 in the learning sample and 0.88 in the validation sample. ConClusions: 
Preliminary results suggest moderate ability of prior structured EMR data to pre-
dict CLOA and good ability of concurrent structured EMR data to identify patients 
with CLOA.
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objeCtives: To estimate the overall response rate [Complete Remission-(CR), 
Partial Remission-(PR), Marrow-CR (MCR)] and Hematologic improvement-(HI) accord-
ing to the International Working Group 2006 criteria to treatment with azacitidine 
amongst patients with Intermediate-2 or High- risk Myelodysplastic Syndromes 
(MDS), in a real world setting in Greece. Methods: A nationwide, retrospective 
chart review study was conducted, based on 17 Hematology departments of Hospitals 
throughout the country. In one single visit the physicians recorded all the pertinent 
data available in the patient’s medical records. In accordance with the inclusion crite-
ria, patients recruited were ≥ 18 years of age and alive at the time of their data collec-
tion, had completed at least one evaluation after azacitidine treatment initiation, and 
received at least one cycle of azacitidine treatment regardless of outcome. Patients also 
gave signed informed consent for blinded analyzation of their medical data. Eligible 
patients had been treated with azacitidine under the terms of the locally approved 
indication (75 mg/m2 SC per day for 7 days every 28 days). Results: 53% of the partici-
pating physicians were located in Attica and enrolled 36% of patients. The mean age 
of 88 patients was estimated at 72.8+ 8.2, with 83% of them aged > 65 years, while the 
male/female ratio was 2.5. The overall response rate was determined at 37.7% and was 
higher for High-risk MDS patients (46.2%) compared with Intermediate-2 patients 
(35.5%). Among the responders, 87% had Refractory Anemia with Excess Blasts 
-RAEB-2, 8.7% had RAEB-1 and 4.3% had Refractory Cytopenias with Unilineage 
Dysplasia. The median number of treatment cycles received to achieve CR, PR, or 
Compliance was calculated during the year after the initiation of the LAI-AP using 
the medication possession ratio (MPR). Patients were considered compliant if they 
had a MPR of at least 0.80. Treatment compliance to oral antipsychotics used in 
the year prior the initiation of the LAI-AP was also evaluated. Results: A total of 
1,992 patients met the inclusion criteria. The mean age was 43.5 years (SD= 14.3) 
and 66.2% of the patients were male. A total of 546 patients (27.4%) received an oral 
antipsychotic at the first date of dispensation of LAI-AP. The average persistence 
with LAI-AP was 217.2 days (SD= 144.2). The mean MPR over the 1-year period fol-
lowing the initiation of LAI-AP was 0.58 (SD= 0.35) for the overall cohort, with 37.5% 
of patients being compliant with a MPR of 0.80 or more, while in the year before 
the initiation of LAI-AP treatment compliance with oral antipsychotics was 29.0% 
(p< 0.001). ConClusions: Treatment persistence and compliance represent signifi-
cant issues in the treatment of schizophrenia/schizoaffective disorders. The initia-
tion of a LAI-AP significantly improved treatment compliance among these patients.
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objeCtives: To analyze treatment patterns of patients receiving paliperidone 
palmitate (PP) in the inpatient setting. Methods: Hospital discharge and billing 
records from the Premier Perspective Comparative Hospital Database (1/2009-3/2012) 
were analyzed for adult patients who had a hospitalization (index hospitalization) 
with a schizophrenia diagnosis (ICD-9: 295.x), and who received their first inpatient 
PP treatment without evidence of prior inpatient treatment with other long-acting 
antipsychotics (AP). Patients with only a schizoaffective disorder diagnosis (ICD-9: 
295.7) during index admission and patients discharged to a psychiatric institute 
were excluded. Length of stay (LOS), time to first PP, and PP dosage frequency and 
strength were used to describe treatment patterns. Statistical comparisons were 
conducted between patients receiving one versus multiple PP doses during hospi-
talization using Wilcoxon rank-sum tests. No adjustment was made for multiplic-
ity. Results: A total of 374 hospitalized patients treated with PP were identified. 
Mean LOS was shorter for one-dose (N= 228) relative to multiple-dose (N= 146) 
patients (11.4 vs. 16.7 days, p< 0.0001) and mean time to first PP was 7.7 and 6.5 
days (p= 0.0161), respectively. Earlier first PP administration was associated with 
shorter LOS (Spearman rank correlation tests: 0.6953 (p< 0.0001) for the one-dose 
and 0.5897 (p< 0.0001) for the multiple-dose cohorts). Among one-dose patients, 
48.2% received a first injection of 234mg. Most multiple-dose patients received a 
first dose of 234mg (70.5%) followed by 156mg (71.2%) as a second dose. The mean 
(SD) time to second PP injection was 5.93 (2.59) days. ConClusions: 39% (146 of 
the 374 patients) of PP patients received multiple PP doses during their inpatient 
stay and had a shorter mean time to treatment initiation compared to one-dose 
patients. Most of these patients received the labeled initiation regimen (234mg 
followed by 156mg dose). In both dose cohorts, shorter time to treatment initiation 
was associated with shorter LOS.
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objeCtives: The abuse of prescription opioids in the United States leads to more 
than 16,000 deaths each year, about one death every 35 minutes (Paulozzi et al., 
2011). Our objectives are to develop a novel social network analysis methodology 
to identify and measure prescription drug abuse. Methods: Prescription data were 
retrieved from a large insurance provider for the state of KY and consisted of pre-
scriber IDs, patient IDs, and location across a spectrum of drugs (Schedule drugs, 
and a set of ‘control group’ products). Network abstractions of the prescribers were 
generated. Surrogate testing in conjunction with community structure detection 
algorithms were used to investigate possible non-random structure of the prescrip-
tion patterns and identify aberrant prescribers. The results of the network analysis 
were visualized using Geo-spatial layouts based on latitude/longitude. Results: 
Network abstractions of the prescribers revealed intricate wiring patterns across 
schedule drugs unlike those of the drugs in the control group. Surrogate testing 
clearly established significant non-random structure in these networks in contrast 
to those that can be generated by random graph realizations. Aberrant prescrib-
ers were subsequently flagged. Non-random structure was accompanied were 
accompanied by highly connected prescribers and hub-like structure. Geo-spatial 
layout of the scheduled drug networks revealed the dominant prescribers to be 
spread across major cities and patient movements across prescribers over large dis-
tances. Lack of wiring across the drugs in the control group indicated that patients 
taking these drugs do not move across prescribers unlike those taking schedule 
drugs. ConClusions: Our results provide system-level insights into prescription 
patterns and supplements traditional approaches that investigate aggregate statisti-
cal measures across the prescribers in isolation. Its ability to identify non-random 
structure and discern such structures across the various drug classes is noteworthy. 
We believe the proposed approach may prove to be a useful tool in implementing 
effective policies to reduce prescription drug abuse, diversion, and overdose
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objeCtives: Inappropriate use of Atypical Antipsychotics (AAPs) in elderly nurs-
ing home residents is a growing problem in geriatric medicine. The current study 
investigated clinically irrational prescribing of AAPs to elderly nursing home resi-
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The second NMA did not report the definition used; instead, the eligibility criteria 
were defined in terms of the treatments assessed in the randomized controlled trials 
(RCTs). The eligibility criteria adopted in each RCT and the resulting patient popula-
tion characteristics were collected in order to assess comparability among the trials 
in each NMA. Results: The RCTs selected in each of the NMAs adopted diverse 
eligibility criteria based on body surface area (BSA), psoriasis area and severity index 
(PASI) score and exposure or failure to previous therapies. Although many of the 
trials adopted eligibility criteria that aligned with clinical guideline definitions of 
moderate to severe PsO as BSA above 10% and PASI above 10, the resulting ‘moder-
ate to severe’ populations showed wide variation in their baseline characteristics. 
Analogous differences in placebo responses were observed. For example, baseline 
PASI scores ranged from 14 to 23, while the proportion of patients with a 75% reduc-
tion in the PASI scores at 12 weeks varied from 2% to 18% among the trials in each 
NMA. ConClusions: The current definitions of ‘moderate to severe’ PsO do not 
seem enough to guarantee similarity in severity across trials, which may lead to 
imbalance in the distribution of potential effect modifiers across comparisons, and 
consequent bias in the NMA estimates. In the absence of better characterization of 
the patient population, adjusting for baseline risk is advisable.
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objeCtives: Children undergoing surgery often experience anxiety, exhibit nega-
tive behaviors and suffer postoperative pain. Previous studies showed inconsistent 
findings in the effects of therapeutic play intervention on children’s perioperative 
anxiety, negative behaviors and postoperative pain. This study aimed to exam-
ine the effectiveness of a therapeutic play intervention on perioperative anxiety, 
negative emotional manifestation and postoperative pain in children undergoing 
inpatient elective surgery. Methods: A randomized controlled trial with two-
group pre- and post-tests study design was conducted. A total of 106 eligible chil-
dren (6-14 years old) were recruited and randomly allocated to either a control 
group (receiving routine care) (n = 53) or an experimental group (receiving one-
hour therapeutic play intervention in addition to routine care) (n = 53). Outcome 
measures included children’s anxiety, emotional manifestation and postoperative 
pain which were conducted at baseline (3-7 days before the operation), on the 
day of surgery, and around 24 hours after surgery. Repeated measures ANCOVA 
and univariate analysis of covariance were used to analyse the data. Results: 
Children in the experimental group demonstrated no superior result in periop-
erative anxiety (p > 0.05), but indicated significantly fewer negative emotional 
manifestations (p < 0.01) and less postoperative pain (p < 0.01) as compared with 
those in the control group. ConClusions: The therapeutic play intervention is 
superior to usual care in reducing negative behaviors and postoperative pain in 
children undergoing inpatient elective surgery. These findings suggest the need 
of providing the therapeutic play intervention for school-aged children who are 
undergoing inpatient elective surgery.
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objeCtives: Chronic low back pain (CLBP) with or without radiculopathy is a major 
expensive, and disabling condition around the globe. Limited safety and efficacy 
data of various analgesics make difficult in prescribing. Present study aimed at 
assessing the efficacy and safety of combination therapy of pregabalin and ami-
triptyline in patients with CLBP in Indian population. Methods: A longitudinal 
prospective observational study was conducted at pain clinic of a public tertiary 
care hospital. Adult patients suffering from low back pain for > 3 months, and who 
received pregabalin (75-150 mg/day) and amitriptyline (10/25 mg/day) were included 
in the study. Data collected for baseline and follow-ups of monthly through hospital 
visits and telephonic contacting until 6 months for VAS; baseline and 6 months for 
Modified Ostwery low back pain Disability questionnaire (MODQ). Percentage of 
patients achieved > 50% of pain reduction by VAS score (0-100) after six months is 
the primary endpoint. Safety and improvement in quality of life after six months 
assessed as secondary endpoint. Analysis done by one way repeated measures 
anova. Results: A total of 198 patients were included in this study with mean age 
of 44.8+12.4 years, 63% are having BMI > 25kg/m2, and duration of pain 30 (12-60) 
months. Magnetic imaging resonance findings have shown disc bulging (43.9%), disc 
herniation (12.6%), spondylosis (11.1%) and other problems. Significant reduction 
in pain was observed p< 0.01 on VAS score after 6 months follow up. VAS&MODQ 
baseline median (IQR) scores found to be 75(60-90)&52(40-60), and after 6 months 
35(20-50)&41(24-53), no improvement in quality of life found p= 0.08. Dry mouth is 
being the commonest adverse event [in 80 (40.4)]. Other adverse events reported 
are headache, constipation, dizziness and postural hypotension. ConClusions: 
Our results suggest that combination of pregabalin and amitriptyline are efficacious 
and safe in managing CLBP.
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MCR was 7 [range: 2-30]. ConClusions: In this observational descriptive study, 
the efficacy of azacitidine for Intermediate-2 and High-risk MDS patients has 
been reported. However, these findings need to be complemented with more 
statistical data, to have a more accurate picture of azacitidine in community practice.
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objeCtives: Obesity is a major health crisis with vast economic and population-
health implications. Effective pharmacological therapies for weight management 
are desirable, yet few have been approved by the Food and Drug Administration 
(FDA) since the withdrawal of fenfluramine/phentermine in the late 1990’s. 
Recently a new product, combination phentermine/topiramate, obtained mar-
keting approval. Both phentermine monotherapy and topiramate monotherapy 
were previously investigated for weight loss, yet only one study compared this 
new combination product to its respective components. The goal of this current 
meta-analysis was to compare the effectiveness of phentermine monotherapy, 
topiramate monotherapy, and phentermine/topiramate combination therapy in 
weight reduction treatment. Methods: Studies were identified from published 
meta-analyses, pharmacological weight loss review articles, and electronic data-
bases including PubMED and ClinicalTrials.gov. Eligible studies were randomized 
placebo-controlled trials with the objective of weight loss assessment. Data from 6 
studies of combination phentermine/topiramate, 10 studies of topiramate mono-
therapy, and 9 studies of phentermine monotherapy were included for analysis. 
Pooled analysis of mean percent weight change was performed using a random 
effects model. Intervention-induced weight loss was assessed and described over-
all and in relation to pooled weight loss estimates of subjects receiving control 
(placebo) treatment. Results: Phentermine/topiramate combination therapy 
had a mean percent weight loss above placebo of 7.18% (95% CI -8.22 to -6.14%), 
a treatment effect larger than the mean percent weight loss above placebo of 
4.57% (95% CI -5.39 to -3.76%) calculated for topiramate monotherapy or the mean 
percent weight loss above placebo of 5.79% (95% CI -6.82 to -4.75%) calculated for 
phentermine monotherapy. ConClusions: Pooled clinical trial data show that 
phentermine/topiramate combination therapy is more effective than topiramate 
monotherapy and phentermine monotherapy in reducing weight. Future studies 
to assess the effectiveness of phentermine/topiramate combination therapy are 
merited to determine if these controlled trial-derived weight loss results translate 
to real-world clinical success.
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objeCtives: Pain is an important driver of quality of life and health care resource 
use, though few treatments are available to effectively treat neuropathic pain. The 
purpose of this study was to characterise the retreatment interval, patch usage 
and clinical effectiveness of the capsaicin 8% patch ‘Qutenza’ (QTZ) when used 
to treat peripheral neuropathic pain in clinical practice. Methods: Interim data 
were available from a prospective, observational study of people with neuropathic 
pain treated with QTZ throughout Europe (n= 340); the ASCEND study. The Numeric 
Pain Rating Scale (NPRS) recorded pain on an integer scale between 0 (no pain) 
and 10 (worst imaginable pain). Time to retreatment was evaluated using the 
Kaplan-Meier method, accounting for right-censored observations. Change 
in pain severity was evaluated using independent sample and paired sam-
ples t-tests. Results: At baseline, the mean NPRS was 6.82 (SD 1.89). At eight 
weeks following first treatment, 43.8% of patients achieved a 30% reduction 
and 24.2% a 50% reduction. In this analysis, 105 (30.9%) patients were retreated 
with QTZ at least once, of which 26 (7.7%) had two re-treatments, and 5 (1.5%) 
had three or more re-treatments. There was no difference in baseline NPRS 
between those that progressed to receiving multiple treatments and those 
treated once (mean NPRS= 6.87 vs. 6.67 units respectively (p= 0.355)). Mean NPRS 
prior to the second application was 5.66 (2.09; p< 0.001), and 5.19 (2.38; p= 0.010) 
prior to subsequent applications. The mean number of patches used at the first, 
second and third applications was 1.18 (0.81), 1.16 (0.75), and 1.19 (1.07), respec-
tively (p= 0.115, p= 0.214). The median time from first to second treatment was 
22 weeks (95% CI 17―27), and from second to third a further 21 weeks (95% CI 
16―26). ConClusions: This study shows that capsaicin 8% patch use and retreat-
ment intervals are stable across successive treatments suggesting consistent 
efficacy.
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COMPARAbIlITY Of TRIAl POPulATIONS IN NETWORk META-ANAlYSES 
ASSESSINg bIOlOgIC TREATMENTS IN MODERATE TO SEvERE PlAQuE 
PSORIASIS
Smiechowski B, Chen M, Vieira MC
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objeCtives: To assess the comparability of the trials included in network meta-
analyses (NMAs) comparing biologic treatments in moderate to severe plaque 
psoriasis (PsO). Methods: A systematic literature review identified two recently 
published NMAs. The definition of ‘moderate to severe’ psoriasis adopted by one 
of the NMAs was “having an inadequate response to topical treatments alone and 
either having received prior systemic therapy or being candidate for such therapy”. 
